Indo National Reports ₹26.69 Cr FY26 Loss, Recommends Dividend

Indo National Limited announced its audited financial results for the fiscal year ended March 31, 2026, reporting a consolidated net loss of ₹26.69 crore. The company also posted a standalone net loss of ₹10.40 crore for the same period.

Despite these losses, the Board of Directors has recommended a final dividend of ₹3.75 per share, subject to shareholder approval. This mirrors the dividend payout from the previous fiscal year, when ₹2.50 per share was recommended.

The company's statutory auditors issued an unmodified opinion on the financial results, confirming no significant accounting concerns. The re-appointment of the Cost Auditor and Internal Auditor was also approved by the board.

Strategic Investments and Amalgamation Underway

Indo National is actively pursuing structural changes aimed at boosting future profitability. During FY26, the company invested ₹693.63 lakh in Medcuore Medical Solutions, establishing it as a subsidiary. Additionally, an amalgamation with Helios Strategic Systems received approval from the National Company Law Tribunal (NCLT) and became effective in April 2026.

Financial Performance and Peer Context

The company has experienced consolidated net losses for the past three fiscal years, with prior-year losses recorded at ₹18.13 crore in FY25 and ₹12.81 crore in FY24.

In comparison, key competitors such as Linc Pen and Plastics Ltd reported a consolidated profit of ₹55.8 crore for FY24. Cello World Ltd also maintains a significant presence in the writing instruments market.

What Investors Should Watch

Investors will be closely monitoring the formal publication of the audited financial results and the shareholder vote on the proposed dividend. The successful integration of Medcuore Medical Solutions and the operational impact of the Helios Strategic Systems amalgamation will be critical factors for future revenue growth and a return to profitability. Management commentary on these strategies will also be important.